BiotechTube
AssayGate

AssayGate

Pre-clinical
San Diego, United StatesFounded 2008assaygate.com

AssayGate, Inc. is a specialized bioanalytical service provider dedicated to delivering comprehensive and cost-effective biomarker testing with a focus on scientific integrity and client collaboration. With over 20 years of collective experience, its team of PhD scientists develops custom assays and provides validated testing services across multiple high-performance platforms, including Olink, Simoa, and MSD-ECL. The company operates as an Olink Certified Laboratory and partners with technology leaders like Quanterix to support pharmaceutical and biotech clients in translational medicine and biomarker discovery.

Market Cap
Private
Pipeline
—
Patents
—
Publications
—

Private Company

Funding information not available

AI Company Overview

AssayGate, Inc. is a specialized bioanalytical service provider dedicated to delivering comprehensive and cost-effective biomarker testing with a focus on scientific integrity and client collaboration. With over 20 years of collective experience, its team of PhD scientists develops custom assays and provides validated testing services across multiple high-performance platforms, including Olink, Simoa, and MSD-ECL. The company operates as an Olink Certified Laboratory and partners with technology leaders like Quanterix to support pharmaceutical and biotech clients in translational medicine and biomarker discovery.

DiagnosticsAntibodies

Technology Platform

AssayGate leverages a multi-platform suite of commercial immunoassay technologies including Luminex xMAP, MSD-ECL, Olink PEA, and Quanterix Simoa to provide customized, high-sensitivity, and multiplexed protein biomarker testing services.

Opportunities

Growth is driven by increasing demand for outsourced, high-complexity biomarker testing in drug development and precision medicine.
Expanding partnerships with platform vendors like Quanterix and Olink, and offering integrated data analysis services, present significant opportunities to capture more value from the growing proteomics market.

Risk Factors

Key risks include dependence on the R&D spending cycles of biopharma clients, intense competition from larger CROs, reliance on third-party technology platforms, and operational risks related to service quality and data integrity.
As a smaller player, scaling and maintaining a differentiated value proposition is an ongoing challenge.

Competitive Landscape

AssayGate competes with large full-service CROs (e.g., LabCorp, IQVIA) and specialized biomarker labs. Its differentiation lies in offering a flexible, multi-platform approach (Luminex, MSD, Olink, Simoa, ELISA), cost-effective pricing, deep scientific expertise for custom work, and certifications as an Olink and Quanterix partner.